Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
Beatson, GT (1896). On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet, 2, 104-7.
Clemons, M., & Goss, P. (2001). Estrogen and the risk of breast cancer. N engl J med, 344(4), 276-285.
“Estrogen receptors/SERMS,” (n.d.). In National cancer institute. Retrieved from http://www.cancer.gov/cancertopics/understandingcancer/estrogenreceptors/AllPages
“Facts for life tamoxifen,” (2010). In Susan g. komen for the cure. Retrieved from http://ww5.komen.org/uploadedfiles/content_binaries/806-326a.pdf
“Facts for life aromatase inhibitors” (2010). In Susan g. komen for the cure. Retrieved from http://ww5.komen.org/uploadedFiles/Content_Binaries/806-03910.pdf
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., ... & Volmark, N. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90(18), 1371-1388.
Goss, P. E., & Strasser-Weippl, K. (2004). Aromatase inhibitors for chemoprevention. Best Practice & Research Clinical Endocrinology & Metabolism, 18(1), 113-130.
Howell, A., & Dowsett, M. (1997). Recent advances in endocrine therapy of breast cancer. BMJ, 315(7112), 863-866.
Johnston, S. R., & Dowsett, M. (2003). Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Reviews Cancer, 3(11), 821-831.
Jordan, V. C. (1988). The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast cancer research and treatment, 11(3), 197-209.
Jordan, V. C., & Morrow, M. (1999). Tamoxifen, raloxifene, and the prevention of breast cancer. Endocrine reviews, 20(3), 253-278.
Lacassagne, A. (1936). Hormonal pathogenesis of adenocarcinoma of the breast. The American Journal of Cancer, 27(2), 217-228.
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., ... & Dugan, M. (2001). Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology, 19(10), 2596-2606.
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., ... & Von Euler, M. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Journal of Clinical Oncology,18(22), 3758-3767.
Ramaswamy, B., Lu, Y., Teng, K. Y., Nuovo, G., Li, X., Shapiro, C. L., & Majumder, S. (2012). Hedgehog signaling is a novel therapeutic target in tamoxifen resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Research.
Smith, I. E., & Dowsett, M. (2003). Aromatase inhibitors in breast cancer. New England Journal of Medicine, 348(24), 2431-2442.
Stockwell, S. (2008). Classics in oncology: George thomas beatson md (1848‐1933). CA: A Cancer Journal for Clinicians, 33(2), 105-107.
1896: George Beatson
1936: Antoine Lacassagne
1962: Jensen and Jacobson
1962: Tamoxifen discovered
1970s: First aromatase inhibitor (aminoglutethimide) used to treat advanced breast cancer
Questions??
Erin Ong
BSCI338G
National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 Study (1998)
Johnston & Dowsett, Nature Reviews Cancer, 3: 821-831, 2003
Fisher et al., Journal of the National Cancer Institute, 90:1377-1388, 1998
Fisher et al., Journal of the National Cancer Institute, 90:1377-1388, 1998
North American Multicenter Randomized Trial (2000)
Time to progression medians: for letrozole 41 weeks (9.4 months); for tamoxifen median TTP was 26 weeks (6.0 months).
Naboltz et al., Journal of Clinical Oncology, 18:3758-3767, 2000
Mouridson et al., Journal of Clinical Oncology, 19:2596-2606, 2001